

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM S-8  
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**Bellicum Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation or organization)

**20-1450200**  
(I.R.S. Employer Identification No.)

**3730 Kirby Dr., Ste. 1200  
Houston, Texas**  
(Address of Principal Executive Offices)

**77098**  
(Zip Code)

**Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan**  
(Full title of the plan)

**Richard A. Fair**  
**President and Chief Executive Officer**  
**Bellicum Pharmaceuticals, Inc.**  
**3730 Kirby Dr., Ste. 1200**  
**Houston, Texas 77098**  
**(281) 454-3424**  
(Name, address, including zip code, and telephone number, including area code, of agent for service)

**Copies to:**

**Karen E. Deschaine, Esq.**  
**Phillip S. McGill, Esq.**  
**Cooley LLP**  
**4401 Eastgate Mall**  
**San Diego, California 92121**  
**Tel: (858) 550-6000**

**Richard A. Fair**  
**President and Chief Executive Officer**  
**Bellicum Pharmaceuticals, Inc.**  
**3730 Kirby Dr., Ste. 1200**  
**Houston, Texas 77098**  
**(281) 454-3424**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

- |                         |                                     |                           |                                     |
|-------------------------|-------------------------------------|---------------------------|-------------------------------------|
| Large Accelerated filer | <input type="checkbox"/>            | Accelerated filer         | <input type="checkbox"/>            |
| Non-accelerated filer   | <input checked="" type="checkbox"/> | Smaller reporting company | <input checked="" type="checkbox"/> |
|                         |                                     | Emerging growth company   | <input type="checkbox"/>            |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

## EXPLANATORY NOTE

The Registration Statement is being filed for the purpose of registering an additional 2,250,000 shares of the Registrant's common stock, par value \$0.01 per share, the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended (the "2019 Plan") are effective.

## INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8

The Registrant previously registered shares of its Common Stock for issuance under the 2019 Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on [June 24, 2019 \(File No. 333-232304\)](#), [July 23, 2019 \(File No. 333-232774\)](#) and [January 29, 2020 \(File No. 333-236149\)](#) and [August 6, 2020 \(File No. 333-241675\)](#). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

### ITEM 8. EXHIBITS.

Exhibit Number	Description
4.1 <sup>(1)</sup>	<a href="#">Amended and Restated Certificate of Incorporation, as amended by the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant and the Second Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant.</a>
4.2 <sup>(2)</sup>	<a href="#">Certificate of Designations, Preferences and Rights of Series 1 Redeemable Convertible Non-Voting Preferred Stock, Series 2 Redeemable Convertible Non-Voting Preferred Stock and Series 3 Redeemable Convertible Non-Voting Preferred Stock of Bellicum Pharmaceuticals, Inc.</a>
4.3 <sup>(3)</sup>	<a href="#">Amended and Restated Bylaws of the Registrant.</a>
4.4 <sup>(4)</sup>	<a href="#">Form of Common Stock Certificate of the Registrant.</a>
4.6 <sup>(5)</sup>	<a href="#">Registration Rights Agreement by and among the Registrant and Baker Brothers Life Sciences, LP, and two of its affiliated funds, dated January 15, 2016.</a>
4.7 <sup>(6)</sup>	<a href="#">Form of Warrant issued in public offering.</a>
4.8 <sup>(7)</sup>	<a href="#">Form of Warrant issued in private offering.</a>
4.9 <sup>(8)</sup>	<a href="#">Securities Purchase Agreement, dated August 16, 2019, by and among the Company and the institutional investors named therein.</a>
4.10 <sup>(9)</sup>	<a href="#">Form of pre-funded warrant.</a>
4.11 <sup>(10)</sup>	<a href="#">Form of warrant to purchase common stock.</a>
4.12 <sup>(11)</sup>	<a href="#">Securities Purchase Agreement, dated December 4, 2021, by and among the Company, Baker Brothers Life Sciences, LP, and Boxer Capital, LLC.</a>
4.13 <sup>(12)</sup>	<a href="#">Form of pre-funded warrant issued in December 2021 private placement.</a>
4.14 <sup>(13)</sup>	<a href="#">Form of accompanying common warrant issued in December 2021 private placement.</a>
5.1*	<a href="#">Opinion of Cooley LLP.</a>
23.1*	<a href="#">Consent of Independent Registered Public Accounting Firm.</a>
23.2*	<a href="#">Consent of Cooley LLP. Reference is made to Exhibit 5.1.</a>
24.1*	Power of Attorney. Reference is made to the signature page hereto.
99.1 <sup>(11)</sup>	<a href="#">Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended.</a>
107*	<a href="#">Filing Fee Table.</a>

- 
- (1) Previously filed as Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q filed with the Commission on August 6, 2020, and incorporated herein by reference.
  - (2) Previously filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed with the Commission on August 19, 2019, and incorporated herein by reference.
  - (3) Previously filed as Exhibit 3.2 to the Registrant's Current Report on Form 8-K, filed with the Commission on December 23, 2014, and incorporated herein by reference.

- (4) Previously filed as Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-200328), originally filed with the Commission on November 18, 2014, as amended, and incorporated herein by reference.
  - (5) Previously filed as Exhibit 4.4 to the Registrant's Annual Report on Form 10-K, filed with the Commission on March 14, 2016, and incorporated herein by reference.
  - (6) Previously filed as Exhibit 4.1 to the Registrant's Current Report on Form 8-K, filed with the Commission on August 19, 2019, and incorporated herein by reference.
  - (7) Previously filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K, filed with the Commission on August 19, 2019, and incorporated herein by reference.
  - (8) Previously filed as Exhibit 10.1 to the Registrant's Current Report on Form 8-K, filed with the Commission on August 19, 2019, and incorporated herein by reference.
  - (9) Previously filed as Exhibit 4.1 to the Registrant's Current Report on Form 8-K, filed with the Commission on November 2, 2020, and incorporated herein by reference.
  - (10) Previously filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K, filed with the Commission on November 2, 2020, and incorporated herein by reference.
  - (11) Previously filed as Exhibit 10.1 to the Registrant's Current Report on Form 8-K, filed with the Commission on December 6, 2021, and incorporated herein by reference.
  - (12) Previously filed as Exhibit 4.1 to the Registrant's Current Report on Form 8-K, filed with the Commission on December 6, 2021, and incorporated herein by reference.
  - (13) Previously filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K, filed with the Commission on December 6, 2021, and incorporated herein by reference.
  - (14) Previously filed as Exhibit 10.1 to the Registrant's Current Report on Form 8-K, filed with the Commission on June 16, 2022, and incorporated herein by reference.
- \* Filed herewith

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, State of Texas, on August 11, 2022.

### Bellicum Pharmaceuticals, Inc.

By: /s/ Richard A. Fair  
Richard A. Fair  
President and Chief Executive Officer

## POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Richard A. Fair, as his or her true and lawful attorney-in-fact and agent, with the full power of substitution, for him and in his name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Richard A. Fair</u> Richard A. Fair	President, Chief Executive Officer and Director <i>(Principal Executive Officer and Principal Financial Officer)</i> <i>(Principal Accounting Officer)</i>	August 11, 2022
<u>/s/ Charles S. Grass</u> Charles S. Grass		August 11, 2022
<u>/s/ Jon P. Stonehouse</u> Jon P. Stonehouse	Director <i>(Chairman)</i>	August 11, 2022
<u>/s/ James M. Daly</u> James M. Daly	Director	August 11, 2022
<u>/s/ Stephen R. Davis</u> Stephen R. Davis	Director	August 11, 2022
<u>/s/ Reid M. Huber, Ph.D.</u> Reid M. Huber, Ph.D.	Director	August 11, 2022
<u>/s/ Judith V. Klimovsky, M.D.</u> Judith V. Klimovsky, M.D.	Director	August 11, 2022

## Calculation of Filing Fee Table

**Form S-8**  
(Form Type)

**Bellicum Pharmaceuticals, Inc.**  
(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

Security Type	Security Class Title	Fee Calculation Rule	Amount Registered <sup>(1)</sup>	Proposed Maximum Offering Price Per Share	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
Equity	<b>2019 Equity Incentive Plan</b> Common Stock, par value \$0.01 per share	Other <sup>(2)</sup>	2,250,000	\$1.36	\$3,060,000	0.0000927	\$283.67
Total Offering Amounts						\$3,127,500	\$283.67
Total Fee Offsets							—
Net Fee Due							\$283.67

- (1) Consists of 2,250,000 additional shares of common stock (the “**Common Stock**”) of Bellicum Pharmaceuticals, Inc. (the “**Registrant**”) available for issuance under the Registrant’s 2019 Equity Incentive Plan, as amended (the “**2019 Plan**”) pursuant to an amendment to the 2019 Plan approved by the Registrant’s stockholders at the Registrant’s Annual Meeting of Stockholders held on June 15, 2022. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “**Securities Act**”), this Registration Statement on Form S-8 shall also cover any additional shares of the Common Stock that become issuable under the 2019 Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding Common Stock.
- (2) This estimate is made pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act solely for purposes of calculating the registration fee. The proposed maximum offering price per unit and maximum aggregate offering price are based upon the average of the high and low prices of the Common Stock on August 8, 2022, as reported on The Nasdaq Capital Market.



August 11, 2022

Bellicum Pharmaceuticals, Inc.  
3730 Kirby Dr., Ste. 1200  
Houston, TX 77098

Ladies and Gentlemen:

We have represented Bellicum Pharmaceuticals, Inc., a Delaware corporation (the "**Company**"), in connection with the filing by the Company of a Registration Statement on Form S-8 (the "**Registration Statement**") with the Securities and Exchange Commission, covering the offering of up to 2,250,000 shares of the Company's Common Stock, par value \$0.01 per share (the "**Shares**"), pursuant to the Company's 2019 Equity Incentive Plan, as amended (the "**Plan**").

In connection with this opinion, we have examined and relied upon the Registration Statement and the related prospectus, the Company's Amended and Restated Certificate of Incorporation, and Amended and Restated Bylaws, each as currently in effect, the Plan and the originals or copies certified to our satisfaction of such other documents, records, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness and authenticity of all documents submitted to us as originals and the conformity to originals of all documents submitted to us as copies thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not sought to independently verify such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement and related prospectus, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements under the Plan, which will be fully paid and nonassessable when such deferred payments are made in full).

We consent to the filing of this opinion as an exhibit to the Registration Statement.

Sincerely,

Cooley LLP

By: /s/ Karen E. Deschaine  
Karen E. Deschaine

### **Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2019 Equity Incentive Plan of Bellicum Pharmaceuticals, Inc. of our report dated March 24, 2022, with respect to the consolidated financial statements of Bellicum Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2021, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Houston, Texas  
August 11, 2022